This volume in the book series ‘Advances in Oto-Rhino-Laryngology’ summarizes the current scientific knowledge of salivary gland neoplasms and illustrates recent advances in this clinical area. Chapters are authored by world-renowned experts who cover the full breadth of salivary gland neoplasms, from benign to malignant, primary to secondary, and pediatric to adult. This comprehensive review highlights the outcome of treatments as well as the classification, diagnosis, and management of salivary gland neoplasms. It also includes a commentary on the future perspective necessary for improvement.

All clinicians, both surgical and non-surgical, involved in the diagnosis and treatment of patients with symptoms and diseases of the salivary gland, will find this book indispensable reading. It is also a beneficial educational resource for clinicians, students, and experts in the field.

Contents

Preface: Bradley, P.J.; Eisele, D.W.

• Classification of Salivary Gland Neoplasms: Bradley, P.J.
• Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms: Bradley, P.J.
• Molecular Pathology and Biomarkers: Ha, P.K.; Stenman, G.
• Evaluation: Imaging Studies: Kontzialis, M.; Glaustin, C.M.; Aygun, N.
• Evaluation: Fine Needle Aspiration Cytology, Ultrasound-Guided Core Biopsy and Open Biopsy Techniques: Howlett, D.C.; Triantafyllou, A.
• Facial Nerve Monitoring: Guntinas-Lichius, O.; Eisele, D.W.
• Surgery for Benign Salivary Neoplasms: Gillespie, M.B.; Iro, H.
• Recurrent Benign Salivary Gland Neoplasms: Witt, R.L.; Nicolai, P.

• Prognostic Scoring for Malignant Salivary Gland Neoplasms: Vander Poorten V.; Guntinas-Lichius, O.
• Surgery for Primary Malignant Parotid Neoplasms: Deschler D.G.; Eisele, D.W.
• Metastatic Cancer to the Parotid: Clark, J.; Wang, S.
• Surgery for Malignant Submandibular Gland Neoplasms: Silver, N.L.; Chinn, S.B.; Bradley, P.J.; Weber, R.S.
• Surgery for Malignant Sublingual and Minor Salivary Gland Neoplasms: Bradley, P.J.; Ferris, R.L.
• Facial Reconstruction and Rehabilitation: Guntinas-Lichius, O.; Genthner, D.J.; Byrne, P.J.
• Management of Regional Metastases of Malignant Salivary Gland Neoplasms: Medina, J.; Zbären, P.; Bradley, P.J.
• Indications for Salivary Gland Radiotherapy: Thomson, D.J.; Slevin, N.J.; Mendenhall, W.M.
• Chemotherapy and Targeted Therapy: Sen, M.; Prestwich, R.
• Management of Inoperable Malignant Neoplasms: Kiess, A.P.; Quon, H.
• Management of Recurrent Malignant Salivary Neoplasms: Merdad, M.; Richmond, J.D.; Quon, H.
• Salivary Gland Neoplasms in Children and Adolescents: Bradley, P.J.; Eisele, D.W.
• Distant Metastases and Palliative Care: Glazer, T.A.; Shuman, A.G.
• Quality of Life after Salivary Gland Surgery: Wax, M.K.; Talma, Y.P.
• Salivary Gland Neoplasms: Future Perspectives: Eisele, D.W.; Bradley, P.J.

Author Index / Subject Index
Caries Research


Caries Research is the Journal of the European Organization for Caries Research (ORCA), an organization founded in 1953 by Dr. Hans R. Held, Geneva, Switzerland to promote research into dental caries and related matters.

Editor-in-Chief

D. Beighton, London, UK

Associate Editors

P. Anderson, London, UK
M. Barbour, Bristol, UK
G. Burnside, Liverpool, UK
J.C. Carvalho, Brussels, Belgium
J. Cury, Piracicaba, Brazil
A.T. Hara, Indianapolis, Ind., USA
M.-C.D.N.J.M. Huysmans, Nijmegen, The Netherlands
M. Maltz, Porto Alegre, Brazil
H. Meyer-Lueckel, Aachen, Germany
B. Nyvad, Aarhus, Denmark
N. Takahashi, Sendai, Japan
E. Zaura, Amsterdam, The Netherlands

Executive Council 2015/2016

President:
V. Machiulskiene, Kaunas, Lithuania
Past President:
A.G. Schulte, Witten, Germany
Vice-President:
J.C. Carvalho, Brussels, Belgium
Co-President:
C. Rahiotis, Athens, Greece
Secretary-General:
Z. Tóth, Budapest, Hungary
Treasurer:
N. Schlueter, Freiburg, Germany
Editor:
D. Beighton, London, UK
Membership Secretary / Webmaster:
L. Tenuta, Piracicaba, Brazil

Advisory Council 2015/2016

R. Chalas, Lublin, Poland
I. Dige, Aarhus, Denmark
A. Ferreira Zandona, Chapel Hill, N.C., USA
S. Higham, Liverpool, UK
A. Jablonski-Momeni, Marburg, Germany
D. Manton, Melbourne, Vic., Australia
C. Rahiotis, Athens, Greece
J. Rodrigues, Porto Alegre, Brazil
C. Splieth, Greifswald, Germany
F. C. Yanikoglu, Istanbul, Turkey

ORCA Contact Address:
Dr. Z. Tóth
Dept. of Conservative Dentistry
Semmelweis University
Szentkirályi u. 47
H–1088 Budapest
Hungary
Tel.: +361 317 1598
E-mail: toth.zsuzsanna@dent.semmelweis-univ.hu

ORCA Website
http://www.orca-caries-research.org
Guidelines for Authors

Aims and Scope
Caries Research is an international journal, the aim of which is to promote research in dental caries and related fields through the publication of original research and the critical evaluation of research findings. The journal will publish papers on the etiology, pathogenesis, prevention and clinical control or management of dental caries. Papers on health outcomes related to dental caries are also of interest, as are papers on other disorders of dental hard tissues, such as dental erosion. Aspects of caries beyond the stage where the pulp ceases to be vital are outside the scope of the journal. The journal reviews papers dealing with natural products and other bacterial inhibitors that meet specific criteria, details of which are available from the Editor.

Submission
Only manuscripts written in English are considered and should be submitted using the online submission website: www.karger.com/crc.

Materials and Methods (or Subjects and Methods):
Includes the design of the experiment or study, the study population sample forming the subject of the research, relevant attributes of the material (e.g. tissue, patients or population sample) forming the subject of the research and state the hypotheses to be tested.

Introduction:
This section should provide a concise summary of the background to the relevant field of research, introduce the specific problem addressed by the study and state the hypotheses to be tested.

Main text:
Letters to the Editor, commenting on recent papers in the journal, are published occasionally, together with a response from the authors of the paper concerned.

Preparation of Manuscripts

Title page:
• the title, which should be informative but concise;
• the authors’ names and initials, without degrees or professional status, followed by their institutes;
• a short title, maximum length 60 characters and spaces, for use as a running head;
• a list of 3–10 keywords;
• the name of the corresponding author and full contact details (postal address and email address).

Disclosure Statement:
Potential conflicts of interest should be identified for each individual author and, if there are none, this should be stated explicitly. A conflict of interest arises when an author has a personal, financial, or financial relationship that might introduce bias or affect their judgement. Examples of situations where a conflict of interest might arise include restrictive conditions in the funding of the research, or if an author or their employer holds patent(s) on a product used in the study, or if any payment is made to an investigator from organizations with an interest in the study (including employment, consultancy, honoraria, ownership of shares, travel grants).

In addition, all authors are required to disclose any potential conflicts to all study participants and should make a statement to confirm that they have done so.

The existence of a conflict of interest does not automatically preclude the consideration of a manuscript for publication, but the Editor might consider it appropriate to publish the information disclosed to him alongside the paper.

The computer software and the statistical methods used throughout the text. All pages and all lines must be numbered, starting from the title page. A conventional font, such as Times New Roman or Arial, should be used, with a font size of 11 or 12. Avoid using italics except for titles, headings, and statistical variables.


Manuscripts reporting studies on human subjects should include evidence that the research was conducted ethically and in accordance with the Declaration of Helsinki (World Medical Association). In particular, there must be a statement in the Materials and Methods section that the consent of an appropriate ethical committee had been obtained prior to the start of the study, and that the subjects were volunteers who had given written informed consent.

Information detailing the power and sample size calculations must be included in the manuscript.

Randomized clinical trials should be reported according to the standardized protocol of the CONSORT Statement. The CONSORT checklist must be submitted together with all papers reporting clinical trials. Reports on observational studies in epidemiology should be structured according to the standardized protocol of the STROBE Statement (http://www.strobe-statement.org/index.php?id=strobe-home). The STROBE checklist must be submitted together with all papers reporting observational studies in epidemiology.

Reports on systematic reviews and meta-analyses should be structured to comply with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (http://www.prisma-statement.org/statement.htm). A PRISMA checklist must be submitted together with all papers reporting systematic reviews and meta-analyses.

The reporting of diagnostic accuracy studies should be carried out according to the criteria described in the STARD Statement (http://www.stard-statement.org/).

The STARD checklist must be submitted together with all papers reporting diagnostic investigations which include clinical and/ or laboratory measurements.

Randomized clinical trials must be registered at clinicaltrials.gov or a similar national authority and the trial number must be included in the manuscript. When submitting a paper on a clinical trial, the trial registration number should be stated at the end of the abstract using the following format: trial registration (name of the trial registry, the registry URL and the trial registration number).

In studies on laboratory animals, the experimental procedures should conform to the principles laid down in the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes and/or the National Research Council Guide for the Care and Use of Laboratory Animals.

Unless the purpose of a paper is to compare specific systems or products, commercial names of clinical and scientific equipment or techniques should only be cited in the Materials and Methods and Acknowledgements sections when appropriate. Elsewhere in the manuscript generic terms should be used.
In any manuscript involving microangiography, the following information must be included: the radiation source and filters used and the kV used (this determines the wavelength of radiation and hence the validity of using Angmar’s equation). Manuscripts on experimental enamel caries should show that the lesions retain a relatively well-preserved surface layer; i.e. that they are not surface-softened lesions. Proof of surface integrity can be provided either as illustrations in the paper or as supplementary material for the reviewers. Transverse microangiography, polarized light microscopy of a section immersed in water or backscattered scanning electron microscopy of a polished cross section can be used to provide the necessary proof. To allow the nature of experimental changes to be assessed, microangiographic or micrographs should be provided to show part of the experimental lesion and the adjacent control as shown in figure 2 of Zaura et al.: Caries Res 2007;41:489–492. Again, these images can be provided as part of the paper or as supplementary material for review purposes.

Results: Results should be presented without interpretation. Identical data should not be presented in both the tables and the figures. The text should not repeat numerical or comparable data from the tables or the figures but should indicate the most important results and describe relevant trends and patterns.

Discussion: This section has the function of describing the limitations of the material or the methods, of interpreting the data and of drawing inferences about the contribution of the study to the wider field of research. There should not be repetition of the preceding sections, e.g. reiteration of results or the aim of the research. The discussion section should include a few sentences summarizing the conclusions of the study. However, there should not be a separate Conclusions section.

Acknowledgements: The contribution of colleagues (for technical assistance, statistical advice, critical comment etc.) should be acknowledged and the position(s) of author(s) employed by commercial firms should be provided. This section should describe the source(s) of funding that have supported the work and should mention any relevant grant numbers. Please also include this sentence: “The funders had no role in the study design, the data collection and the analysis, decision to publish, or the preparation of the manuscript.” If this statement is not correct, you must describe the role of any sponsors or funders, and amend the sentence as needed. Additionally, the roles of all authors must be described. (For example: Conceived and designed the experiments: AA, BB. Performed the clinical examination: AA, CC. Performed the experiments: DD, FF. Analyzed the data: BB. BF. Wrote the paper: AA, CC, FF, EE.)

Legends: The table headings should be listed first, followed by the legends for the illustrations.

Tables: Tables should be numbered in Arabic numerals. Each table should be placed on a separate page. Tables should not be constructed using tabs but should instead be compiled with the help of the table function of the word-processing software.

Illustrations:
- Illustrations should be numbered in Arabic numerals in the sequence of citation. Figure numbers must be clearly visible on the figures themselves, outside the image area.
- Black and white half-tone illustrations must have a final resolution of 300 dpi after scaling and line drawings should have a final resolution of 800–1,200 dpi.
- Figures with a screen background should not be submitted.
- Whenever possible, group several illustrations in a single block for reproduction (max. size 180 × 233 mm).

Color Illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text or figure legend.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References

Reference to other publications should give due acknowledgment to previous work, provide the reader with accurate information on and up-to-date guidance in the field of research under discussion, and it should also provide evidence to support the line of the arguments presented. Authors should select references carefully to fulfill these aims without attempting to be comprehensive. Cited work should already have been published or officially accepted for publication. Material submitted for publication but not yet accepted should be cited as ‘unpublished results’, while unpublished observations communicated to the authors by any other author should be cited as ‘personal communication’, with credit in both cases being given to the source of the information. Material unpublished nor personally communicated material should be included in the list of references. Abstracts that are not more than 2 years old and theses should not be cited without a good reason, which should be explained in the covering letter accompanying the paper.

References should be cited by naming the author(s) and the year. Where references are cited in square brackets, the number of references cited should not exceed 20. Where the author is the subject or object of the sentence, only the year is enclosed in square brackets. The author: [Frostell, 1984] or Frostell [1984].

Two authors: [Dawes and ten Cate, 1990] or Dawes and ten Cate [1990].

More than two authors: [Trahan et al., 1985] or Trahan et al. [1985].

When several references are cited in square brackets, these should be in date order and separated by semicolons: [Frostell, 1984; Trahan et al., 1985; Dawes and ten Cate, 1990].

Material published on the World Wide Web should be cited in the same way as a reference to a publication, and the URL should be included in the reference list (not in the text), together with the year when it was accessed. The reference list should include all the publications cited in the text, but no other publications. References, formatted as in the examples below, should be arranged in strict alphabetical order. All authors should be listed. For papers by the same authors, references should be listed according to the year. Papers published by the same authors in the same year should be distinguished by adding the letters a, b, c etc. immediately following the year, in both the text citation and the reference list. For abbreviating the names of journals, use the Index Medicus system. For journals, provide only the year, the volume number, and the page numbers.

Examples

(b) Papers published only with DOI numbers: Theoridis TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Supplementary Material

Supplementary material is restricted to additional information which is directly pertinent to the content and conclusion of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The editors reserve the right to reject or limit the scope and length of supplementary material. Supplementary material must meet production quality standards for web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. Acceptable file formats are word or pdf, excel spreadsheets (only if the data cannot be converted properly to a pdf file), video files (.mov, .avi, .mpg), and audio files (.wav), either as a separated file or incorporated into html or ppt files in each case to illustrate the sound. Accepted supplementary material will be published as submitted and no proofs will be provided to the authors.

Digital Object Identifier (DOI)

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeleyn) no earlier than 12 months following publication of the final version of their article. For self-archiving, the posted manuscripts must:
- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement:

“This is the peer-reviewed but unedited manuscript version of the following article: insert full citation, e.g. Cytozogen Genome Res 2014;142:227–238 (DOI: 10.1159/000363001). The final, published version is available at http://www.karger.com/?doi=insert DOI number).”

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article. Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author’s Choice14 (Gold Open Access) articles, see Author’s Choice19.
Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Re-posted Open Access articles must:

- Follow the terms of the relevant Creative Commons license
- Be linked to the final version on www.karger.com
- Include the following statement:
  ‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMC ID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges
There are no page charges for papers of seven or fewer printed pages (including tables, illustrations and references). A charge of CHF 650.00 will be levied for each page in excess of the allotted seven printed pages. The allotted size of a paper is equal to approximately 21 typescript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations other than the correction of printing errors are charged to the author. No page proofs are supplied to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after an issue is printed are subject to considerably higher prices.

‘A collection of extraordinary essays’
GOTTFRIED SCHATZ
A MATTER OF WONDER
What Biology Reveals about Us, Our World, and Our Dreams

Where do we come from? Is our destiny determined by the genes we inherit? In this book Gottfried Schatz, the world-renowned biochemist and co-discoverer of mitochondrial DNA, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mysteries of life. These essays on key issues in the natural sciences will appeal not only to scientists but to all inquisitive minds, regardless of educational and professional background.

G. Schatz (Basel)
A Matter of Wonder
What Biology Reveals about Us, Our World, and Our Dreams
Translated by A. Shields
XII + 190 p., 2 color fig., hard cover, 2011
CHF 29.00 / EUR 27.00 / USD 29.00

More information and sample essays at www.karger.com/schatz

Gottfried Schatz
A Matter of Wonder
What Biology Reveals about Us, Our World, and Our Dreams

© 2016 S. Karger AG, Basel

The Guidelines for Authors are available at: www.karger.com/cre_Guidelines
13th BIENNIAL CONGRESS
EUROPEAN ASSOCIATION OF ORAL MEDICINE

TOPICS
- PRECANCER AND EARLY CANCER
- ORAL AND SYSTEMIC INFECTIONS
- EFFECTS OF DRUGS ON ORAL HEALTH
- MANAGEMENT OPTIONS IN ORAL ONCOLOGY
- IMMUNOMEDIATED DISEASES
- SPECIAL NEEDS
- CLINICOPATHOLOGIC CONFERENCE
- SUPPORTIVE CARE IN ORAL MEDICINE

LOCAL ORGANIZING COMMITTEE
Sergio Gandolfo
Monica Pentenero
Cristina Bez
Marco Meleti
Paolo Vescovi

ORGANIZING SECRETARIAT
SELENESrl
23, Via Medici 23 – Torino
Phone +390117499601
Fax +390117499576
eaom2016@seleneweb.com

SEPTEMBER 15-17, 2016
TORINO - ITALY
www.eaom2016.com
Contents

See the journal website for contents
The majority of the global population is affected by repair or replacement of craniofacial structures caused by tooth decay or loss as well as major craniofacial defects, necessitating complex tissue augmentation or regeneration procedures. As a result of exciting developments and the increasing number of novel biomaterials and different clinical applications, it is extremely important to understand these biomaterials and their design. This publication integrates the application of biomaterials science and describes the recent advances, the role of cutting-edge biomaterials in engineering oral tissues, surface modification technologies, the emerging field of nanomaterials and clinical translation showing future directions in oral and craniomaxillofacial health care.

Researchers active in dental, medical and biomaterials sciences, oral and maxillofacial surgeons, dentists, tissue engineers as well as materials scientists will find valuable information on the latest progress and novel approaches as will all those who are looking for better solutions to the problems associated with facial deformities.

Contents

Preface: Deb, S.
- Biomaterials in Relation to Dentistry: Deb, S.; Chana, S.
- Polymer Therapeutics in Relation to Dentistry: Rojo, L.; Deb, S.
- Biological Impact of Bioactive Glasses and Their Dissolution Products: Hoppe, A.; Boccaccini, A.R.
- Organic-Inorganic Composites Toward Biomaterial Application: Miyazaki, T.; Sugawara-Narutaki, A.; Ohtsuki, C.
- New Advanced Materials for High Performance at the Resin-Dentine Interface: Toledano, M.; Osorio, R.
- Nanobiomaterial Coatings in Dentistry: Choi, A.H.; Cazalbou, S.; Ben-Nissan, B.
- The Effect of Titanium Surface Modifications on Dental Implant Osseointegration: Annunziata, M.; Guida, L.
- Global Gene Expression Analysis for the Assessment of Nanobiomaterials: Hanagata, N.
- Membranes for Periodontal Regeneration – A Materials Perspective: Bottino, M.C.; Thomas, V.
- Biomaterials in the Reconstruction of the Oral and Maxillofacial Region: Ayoub, A.; Al-Fotawei, R.

Author Index/ Subject Index
Original Papers

271 A Predictive Model for Root Caries Incidence
Ritter, A.V.; Preisser, J.S. (Chapel Hill, N.C.); Puranik, C.P. (Farmington, Conn.); Chung, Y.; Bader, J.D.; Shugars, D.A. (Chapel Hill, N.C.); Makhlouf, S. (Birmingham, Ala.); Vollmer, W.M. (Portland, Oreg.)

279 Insights into the Virulence Traits of Streptococcus mutans in Dentine Carious Lesions of Children with Early Childhood Caries
Bezerra, D.S. (Fortaleza); Stipp, R.N. (Piracicaba); Neves, B.G.; Guedes, S.F.F. (Fortaleza); Nascimento, M.M. (Gainesville, Fla.); Rodrigues, L.K.A. (Fortaleza)

288 Validation of the Oral Survey-B System for Electronic Data Capture in National Oral Health Surveys
Carvalho, J.C. (Brussels); Declerck, D. (Leuven); De Vos, E. (Ghent); Kellen, J.; Van Nieuwenhuysen, J.P. (Brussels); Vanobbergen, J. (Ghent); Bottenberg, P. (Brussels); Declerck, C. (Leuven)

295 Orange/Red Fluorescence of Active Caries by Retrospective Quantitative Light-Induced Fluorescence Image Analysis
Felix Gomez, G.; Eckert, G.J. (Indianapolis, Ind.); Ferreira Zandonà, A. (Chapel Hill, N.C.)

303 Di-Calcium Phosphate and Phytosphingosine as an Innovative Acid-Resistant Treatment to Occlude Dentine Tubules
Sauro, S.; Lin, C.-Y. (Valencia); Bikker, F.J. (Amsterdam); Cama, G.; Dubruel, P. (Ghent); Soria, J.M. (Valencia); D’Onofrio, A.; Gillam, D. (London)

310 Family-Based Genetic Association for Molar-Incisor Hypomineralization
Jeremias, F.; Pierrì, R.A.G. (Araraquara); Souza, J.F. (Paraná); Fragelli, C.M.B.; Restrepo, M.; Finoti, I.S.; Bussaneli, D.G.; Cordeiro, R.C.L. (Araraquara); Secolin, R.; Maurer-Morelli, C.V. (Campinas); Scarel-Caminaga, R.M.; Sant’Anna, L. (Araraquara)

325 In situ Effect of Chewing Gum with and without CPP-ACP on Enamel Surface Hardness Subsequent to ex vivo Acid Challenge

337 In vitro Efficacy of Experimental Chitosan-Containing Solutions as Anti-Erosive Agents in Enamel
Pini, N.I.P. (Giessen/Piracicaba); Lima, D.A.N.L.; Lovadino, J.R. (Piracicaba); Ganss, C. (Giessen); Schlüeter, N. (Giessen/ Freiburg)

Short Communications

319 Breastfeeding, Dental Biofilm Acidogenicity, and Early Childhood Caries
Neves, P.A.M.; Ribeiro, C.C.C. (São Luís); Tenuta, L.M. (Piracicaba); Leitão, T.J.; Monteiro-Neto, V.; Nunes, A.M.M. (São Luís); Cury, J.A. (Piracicaba)

331 Development of a Database of the Fluoride Content of Selected Drinks and Foods in the UK
Zohoori, F.V. (Middlesbrough); Maguire, A. (Newcastle upon Tyne)

346 Announcement

Cover Illustration
For details see paper by Pini et al. (pp. 337–345).